| |
|
|
|
Xtalks, Online
2024-10-10
Cell-based bioassays (CBBAs) are an essential tool for drug development, from preclinical through commercialization and are crucial for monitoring drug manufacturing processes and ensuring the safety, efficacy and potency of pharmaceutical products. These products, particularly cell and gene therapeutics and advanced biologics, are inherently complex.
Therefore, CBBAs must be tailored to suit each program. Choosing the best methods for each modality and understanding the desired endpoints are critical to designing successful assays and keeping your program on track. This webinar will cover fundamental aspects of CBBA development:
Method selection for different modalities with a focus on potency
Understanding key aspects and pitfalls of assay development
Case study on potency assays for antibody-drug conjugates
Importance of a two-way partnership for ensuring speed and staying on track
Register for this webinar today to explore essential strategies for designing and developing successful CBBAs tailored toward the development of advanced therapeutics.
Keywords: Drug Development, Assay Development, Therapeutic Areas, Assay, Cell-Based Assay, Bioanalytical Testing, Bioassays, Pre-Clinical, Cell & Gene Therapies, Basic Research
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Jung-Hua Yeh, PhD, Principal Scientist, Cell-Based BioAssay Department at Solvias
Dr. Reg Clayton, Head of Biosafety and Deputy Site Head, Solvias
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2024-10-10
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|
|